Literature DB >> 15816996

Does C-reactive protein identify a subclinical metabolic disease in healthy subjects?

S Bo1, R Gambino, B Uberti, M P Mangiameli, G Colosso, E Repetti, L Gentile, M Cassader, G F Pagano.   

Abstract

BACKGROUND: Highly sensitive C-reactive protein (hs-CRP) levels are significant predictors of subsequent diabetes and metabolic syndrome (MS). Owing the strong correlations between components of the MS and obesity with hs-CRP levels, previous studies about the associations of hs-CRP with insulin resistance might have been confounded by the inclusion of overweight or dysmetabolic subjects.
DESIGN: Our aim was to evaluate the associations between hs-CRP levels and fasting insulin and insulin resistance (evaluated by the Homeostasis Model Assessment: HOMA IR) in a subgroup of subjects with normal body mass index (BMI) and without any metabolic abnormalities. Out of a cohort of 1658 middle-aged subjects, representative of the local sanitary districts of the province of Asti (north-western Italy) enrolled for metabolic screening: 241 (14.5%) showed normal BMI, glucose tolerance, blood pressure and waist values and no dyslipidaemia.
RESULTS: In this subgroup of subjects, those with hs-CRP levels > or = 3 mg L(-1) showed significantly higher median insulin and HOMA-IR values (respectively: 20.4 vs. 6.0 pmol L(-1), and 0.8 vs. 0.2 microU mL(-1)x mmol L(-1)). In a multiple regression model, insulin and insulin resistance remained significantly and independently related to hs-CRP levels, after adjustments for age, sex, BMI, waist, alcohol consumption, level of physical activity and smoking habits. Very few individuals within lower fasting insulin quartiles showed hs-CRP values > or = 3 mg L(-1) when compared with approximately 60% of those within the highest quartile.
CONCLUSIONS: The novel finding is that a state of low-grade systemic inflammation is present in normal BMI subjects who show subclinical insulin resistance but no other metabolic abnormalities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816996     DOI: 10.1111/j.1365-2362.2005.01490.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Key questions resulting from the JUPITER trial assessing cardiovascular disease intervention with rosuvastatin.

Authors:  Shirya Rashid
Journal:  World J Cardiol       Date:  2009-12-31

2.  Associations between serum uric acid and adipokines, markers of inflammation, and endothelial dysfunction.

Authors:  S Bo; R Gambino; M Durazzo; F Ghione; G Musso; L Gentile; M Cassader; P Cavallo-Perin; G Pagano
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

3.  IL1B gene promoter haplotype pairs predict clinical levels of interleukin-1beta and C-reactive protein.

Authors:  John Rogus; James D Beck; Steven Offenbacher; Kenneth Huttner; Licia Iacoviello; Maria Carmela Latella; Monica de Gaetano; Hwa-Ying Wang; Kenneth S Kornman; Gordon W Duff
Journal:  Hum Genet       Date:  2008-03-28       Impact factor: 4.132

4.  PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin.

Authors:  James T Willerson; Greg Cable; Edward T H Yeh
Journal:  Tex Heart Inst J       Date:  2009

5.  CD14 deficiency impacts glucose homeostasis in mice through altered adrenal tone.

Authors:  James L Young; Alfonso Mora; Anna Cerny; Michael P Czech; Bruce Woda; Evelyn A Kurt-Jones; Robert W Finberg; Silvia Corvera
Journal:  PLoS One       Date:  2012-01-13       Impact factor: 3.240

6.  Postprandial insulin resistance as an early predictor of cardiovascular risk.

Authors:  W Wayne Lautt
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.